AUM LifeTech

University City Science Center
3711 Market Street, Suite 800
Philadelphia
Pennsylvania
19104
United States

Tel: 215-966-6098
Fax: 215-501-7152

About AUM LifeTech

At AUM LifeTech we are taking important steps towards development of personalized medicine at the genetic level. We are working on the development of next generation RNA silencing and regulation therapeutics for a wide spectrum of genetic diseases. In addition, AUM is also making its RNA silencing FANA technology available to scientists and researchers for basic and translational research. For research use, AUM LifeTech provides FANA antisense oligonucleotides for RNA silencing and regulation studies through its subsidiary AUM BioTech. AUM LifeTech is headquartered in Philadelphia, PA at the University City Science Center's Port business incubator.
YEAR FOUNDED:
2013
LEADERSHIP:
Co-Founder & CEO: Veenu Aishwarya
Co-Founder & Chairman: Mahesh Chand
PRODUCTS:
Please click here for AUM LifeTech's products.

8 articles about AUM LifeTech

Philadelphia-based Biotech Company AUM LifeTech Awarded $400,000 NCI/NIH Grant to Advance Their Lung Cancer Immunotherapy Program Using RNA-Targeting Gene Therapy with Checkpoint Inhibitors

8/17/2022

AUM LifeTech, Inc., a Philadelphia-based preclinical stage biotechnology company, has received a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to advance their preclinical program in lung cancer immunotherapy using a non-viral RNA-targeting gene therapy approach.
AUM LifeTech announces collaboration with CSU on a DARPA-funded project to develop non-viral, non-GMO RNA-targeting products for sustainable/precision agriculture

3/8/2022

AUM LifeTech, Inc. announced a collaboration with Colorado State University (CSU) on a DARPA-funded project using AUM LifeTech's self-deliverable RNA Silencing FANA Antisense Oligonucleotides (FANA ASO) technology.
AUM LifeTech awarded NIH grant to develop HIV therapy using RNA targeting technology, commits additional resources to COVID-19 research

8/11/2020

The NIAID funded grant will help advance AUM LifeTech's preclinical program on HIV therapy using self-delivering RNA silencing technology
Biopharma Update on the Novel Coronavirus: May 7

5/7/2020

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.
AUM LifeTech, CHOP and Penn Partnering to Advance Cancer Immunotherapy Against Lung Cancer Using Foxp3 Gene Silencing FANA ASO Therapy

10/10/2018

The preclinical results were presented at the 2018 Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Seattle, WA.
USDA And AUM LifeTech Develop A Novel Non-GMO RNA Silencing Approach Against Citrus Greening With A Goal To Save The Troubled $40 Billion Global Citrus Industry

12/2/2016
AUM LifeTech's Next Generation FANA RNA Silencing Technology Showcased In Several Studies At Oligonucleotide Therapeutics Society Meeting In Montreal, Canada

10/12/2016
AUM LifeTech Develops A New Approach To Combat HIV By Using FANA RNA Silencing Technology To Inhibit HIV Replication

10/6/2016